Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXT3003 in CMT1A (Phase III, China)
CTR20211722Phase 3Completed
- Sponsor
- Tasly Group
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of PXT 3003 in Charcot-Marie-Tooth disease type 1A (CMT1A), sponsored by Tasly Group. Started Sep 2021; status: completed.
02
Drugs
PXT 3003
03
Conditions
Charcot-Marie-Tooth disease type 1A (CMT1A)
Beyond the preview
Go deeper on CTR20211722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211722.